Five patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Nov 2039. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2039
Next term end
3
Patent families
When these terms end
Each bar runs from grant to computed term end. 2020 to 2042.
US 12,038,431
High-Throughput Screening System for Identification of Novel Drugs and Drug Targets
Jul 7, 2042
US 11,802,866
High-Throughput Screening System for Identification of Novel Drugs and Drug Targets
Sep 11, 2042
20252030203520402042
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
4 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2039 · High confidence
Also notable
Ends Sep 2042 · High confidence
Also notable
Ends Jun 2040 · High confidence
Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)
US 10,738,067
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2039.
High-Throughput Screening System for Identification of Novel Drugs and Drug Targets
US 11,802,866
Granted 2023. Computed term ends 2042.
Inhibitors of Cyclin Dependent Kinase 7 (CDK7)
US 11,918,592
Granted 2024. Too new for citation comparison; protection runs to 2040.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 30, 2027The maintenance fee for High-Throughput Screening System for Identification of Novel Drugs and Drug Targets (US 11,802,866) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Inhibitors of Cyclin Dependent Kinase 7 (CDK7) (US 11,918,592) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| High-Throughput Screening System for Identification of Novel Drugs and Drug Targets | 2 in force | to Sep 2042 |
| Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) | 2 in force | to Dec 2041 |
| Inhibitors of Cyclin Dependent Kinase 7 (CDK7) | 1 in force | to Jun 2040 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,738,067 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) In force · High confidence | In force | High confidence | |
| US 11,918,592 | Inhibitors of Cyclin Dependent Kinase 7 (CDK7) In force · High confidence | In force | High confidence | |
| US 12,240,869 | Inhibitors of Cyclin-Dependent Kinase 7 (CDK7) In force · Medium confidence | In force | Medium confidence | |
| US 12,038,431 | High-Throughput Screening System for Identification of Novel Drugs and Drug Targets In force · High confidence | In force | High confidence | |
| US 11,802,866 | High-Throughput Screening System for Identification of Novel Drugs and Drug Targets In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 4 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.